News stories about Idera Pharmaceuticals (NASDAQ:IDRA) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Idera Pharmaceuticals earned a daily sentiment score of 0.05 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 47.0225179358404 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:

Idera Pharmaceuticals (NASDAQ:IDRA) traded up 1.17% during mid-day trading on Friday, reaching $1.73. 1,011,897 shares of the company’s stock traded hands. Idera Pharmaceuticals has a 12-month low of $1.30 and a 12-month high of $3.33. The stock’s market capitalization is $258.86 million. The stock has a 50-day moving average price of $1.83 and a 200-day moving average price of $1.89.

Idera Pharmaceuticals (NASDAQ:IDRA) last released its earnings results on Monday, August 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by $0.03. The firm had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.20 million. Idera Pharmaceuticals had a negative return on equity of 61.09% and a negative net margin of 300.63%. Equities research analysts expect that Idera Pharmaceuticals will post ($0.49) EPS for the current year.

A number of analysts have recently issued reports on IDRA shares. ValuEngine raised shares of Idera Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. Zacks Investment Research raised shares of Idera Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, July 6th. Robert W. Baird started coverage on shares of Idera Pharmaceuticals in a report on Monday, April 24th. They set an “outperform” rating and a $5.00 price objective for the company. Finally, BidaskClub downgraded shares of Idera Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Three equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company. Idera Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $4.57.

COPYRIGHT VIOLATION NOTICE: “Idera Pharmaceuticals (IDRA) Earning Somewhat Favorable Press Coverage, Analysis Shows” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at

Idera Pharmaceuticals Company Profile

Idera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology.

Insider Buying and Selling by Quarter for Idera Pharmaceuticals (NASDAQ:IDRA)

Receive News & Ratings for Idera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.